Key result
The identification and management of patients at high bleeding risk during and after percutaneous coronary interventions remains problematic in everyday clinical practice.
Why the study?
The identification and management of patients at high bleeding risk during and after PCI remains problematic in everyday clinical practice.
The identification and management of patients at high bleeding risk during and after PCI remains a challenge in clinical practice.
Answers are grounded in this paper and cite their sources.
Ongoing HBR challenges in PCI highlight practice gaps; leaves open standardized tools and prospective trials.
The progress of percutaneous coronary interventions (PCI) over the last few decades facilitated treatment of increasingly complex patient populations. The introduction of drug-eluting stents (DESs) led to need of stronger and prolonged inhibition of platelets which in turn increased the incidence of bleeding complications. The identification and management of patients at high bleeding risk (HBR) during and after percutaneous coronary interventions (PCI) is still problematic in everyday clinical practice.
No takes yet. Share an insight, caveat, or question.
Zheleva et al. (2020) conducted a review in High bleeding risk after percutaneous coronary interventions. Antiplatelet therapy was evaluated. The identification and management of patients at high bleeding risk during and after percutaneous coronary interventions remains problematic in everyday clinical practice.
Synapse has enriched 10 related papers. Consider them for comparative context: